Does lapatinib work against HER2-negative breast cancers?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20179241.
- Also identified by DOI 10.1158/1078-0432.CCR-09-3223 and PMC identifier 3448974.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aberrant growth factor receptor signaling can augment or suppress estrogen receptor (ER) function in hormone-dependent breast cancer cells and lead to escape from anti-estrogen therapy. Interruption of HER2/ER cross-talk with lapatinib can restore sensitivity to anti-estrogens and thus, should be investigated in combination with endocrine therapy in patients with ER+/HER2-negative breast cancers.
Medical subject headings
- Antineoplastic Agents
- Breast Neoplasms
- Quinazolines
- Receptor Cross-Talk
- Erb-b2 Receptor Tyrosine Kinases